Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-07-31
2011-10-04
Bausch, Sarae (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S006110, C435S006130, C435S006180, C435S091100, C436S063000
Reexamination Certificate
active
08029998
ABSTRACT:
Methods and kits for predicting the efficacy of antifolate (e.g., methotrexate) treatment of rheumatoid arthritis by detecting polymorphisms, particularly single nucleotide polymorphisms, in adenosine pathway genes.
REFERENCES:
patent: 7702469 (2010-04-01), Huizinga et al.
patent: 7713696 (2010-05-01), Guchelaar et al.
patent: 2007/0238103 (2007-10-01), Guchelaar et al.
patent: 2008/0288177 (2008-11-01), Guchelaar et al.
patent: 2010/0240541 (2010-09-01), Guchelaar et al.
AMPD1 Gene, Adenosine monophosphate deaminase 1 gene, pp. 1-16, available at genecards.org, printed Aug. 13, 2008.
Alethaha et al., Remission and Active Disease in Rheumatoid Arthritis, Defining Criteria for Disease Activity Status, Arthritis & Rheumatism, vol. 52, No. 9, 2625-2636, (2005).
Alethaha et al., The Rheumatoid Arthritis Patient in the Clinic: Comparing more than 1300 Consecutive DMARD Courses, Rheumatology, vol. 41, 1367-1374, (2002).
Anderson et al., Factors Predicting Response to Treatment in Rheumatoid Arthritis, Arthritis & Rheumatism, vol. 43 No. 1, 22-29, (2000).
Bosco et al., Methionine Synthase (MTR) 2756 (A→G) Polymorphism, Double Heterozygosity Methionine Synthase 2756/AG Methionine Synthase Reductase (MTRR) 66 AG, and Elevated Homocysteinemia Are Three Factors for Having a Child with Down Syndrome, American Journal of Medical Genetics, vol. 121A, 219-224, (2003).
Bulock et al., The Kinetic Mechanism of the Human Bifunctional Enzyme 5-Aminoimidazole-Carboxamide Ribonucleotide Formyltransferase/Inosince 5′—Monophosphate Cyclohydrolase: A Surprising Lack of Substate Channeling, The Journal of Biological Chemistry, vol. 277 No. 25, 22168-22174, (2002).
Cao et al., DNA Polymorphisms in ITPA including basis of inosine triphosphatease deficiency, J Hum Genet, vol. 47, 620-622, (2002).
Chan et al. Molecular Action of Methotrexate in inflammatory Diseases, Arthritis Research, vol. 4, No. 4, 266-273, 2002.
Cronstein et al., Methotrexate inhibits Neutrophil Function by Stimulating Adenosine Release from Connective Tissue Cells, Proc. Natl. Acad. Sci. USA, vol. 88, 2441-2445, (1991).
Cronstein, Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis, Pharmacological Reviews, vol. 57, No. 2, 163-172, (2005).
Cutolo et al., Anti-inflammatory Mechanisms of Methotrexate in Rheumatoid Arthritis, Annals of the Rheumatic Diseases, vol. 60, 729-735, (2001).
Delano et al., Genetically Based Resistance to the Anti-inflammatory Effects of Methotrexate in the Air-Pouch Model of Acute Inflammation, Arthritis & Rheumatism, vol. 52, No. 8, 2567-2575, (2005).
Dervieux et al., Polyglutamation of Methotrexate with common Polymorphisms in reduced folate carrier, Aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis, Arthritis & Rheumatism, vol. 50, No. 9, 2766-2774, (2004).
Evans et al., Pharmacogenomics—Drug Disposition, Drug Targets, and Side Effects, The New England Journal of Medicine, vol. 348, No. 6, 538-549, (2003).
Gaughan et al., The Methionine Synthase Reductase (MTRR) A66G Polymporphism is a novel genetic determinant of plasma homocysteine concentrations, Atheroslerosis, vol. 157, 451-456, (2001).
GeneCards, Adenoise monophosphate deaminase 1 (isoform M) pp. 1-16, available at genecards.org., printed Aug. 2008.
Genovese et al., Etanercept Versus Methotrexate in Patients with Early Rheumatoid Arthritis, Arthritis & Rheumatism, vol. 46 No. 6, 1443-1450, (2002).
Goekoop-Ruiterman et al., Clinical and Radiographic Outcomes of Four Different Treatment Strategies in Patients with Early Rheumatoid Arthritis (the BeSt Study), a Randomized, Controlled Trial, Arthritis & Rheumatism, vol. 52, No. 11, 3381-3390, (2005).
Gossec et al., Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study, Annals of the Rheumatic Diseases, vol. 63, 675-680, (2004).
Hattersley et al., Genetic Epidemiology. 5, What makes a good genetic association study? The Lancet, vol. 366, 1315-1323, (2005).
Hider, S.L., et al., The Pharmacogenetics of Methotrexate, Rheumatology, 2007, 46: 1520-1524.
Huizinga et al., Associations, Populations, and the Truth, Arthritis & Rheumatism, vol. 50, No. 7, 2066-2071, (2004).
Ioannidis et al., Replication Validity of Genetic Association Studies, Nature Genetics, vol. 29, 306-309, (2001).
Israel et al., Use of Regularly Scheduled Albuterol Treatment in Asthma: Genotype-Stratified, Randomised, Placebo-controlled cross-over trial, The Lancet, vol. 364, 1505-1512, (2004).
Kalsi et al., Decreased Cardiac Activity of AMP Deaminase in Subjects with the AMPD1 Mutation—A potential Mechanism of Protection in heart failure, Cardiovascular Research, vol. 59, 678-684, (2003).
Klareskog et al., Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial, The Lancet, vol. 363, 675-681, (2004).
Lucia, et al., “C34T mutation of the AMPD1 gene in an elite white runner”, Br J Sports Med, 2006 vol. e7, pp. 1-3.
Marinaki et al., Adverse Drug Reactions to Azathioprine Therapy are Associated with Polymorphism in the Gene Encoding Inosine Triphosphate Pyrophosphatase (ITPase), Pharmacogenetics, vol. 14, No. 3, 181-187, (2004).
Matteson et al., How Aggressive Should Initial Therapy for Rheumatoid Arthritis be? Factors Associated with Response to ‘non-aggressive’ DMARD Treatment and Perspective from a two-year Open Label Trial, Rheumatology, vol. 43, 619-625, (2004).
Montesinos et al., Adenosine A2aor A3Receptors are Required for Inhibition of Inflammation by Methotrexate and Its Analog MX-68, Arthritis & Rheumatism, vol. 48, No. 1, 240-247, (2003).
Morabito et al., Methotrexate and Sulfasalazine Promote Adenosine Release by a Mechanism that Requires Ecto-5-Nucleotidase-mediated Conversion of Adenine Neucleotides, J. Clinical Investigation, vol. 101, No. 2, 295-300, (1998).
Morisaki et al., Molecular basis of AMP Deaminase Deficiency in Skeletal Muscle, Proc. Natl. Acad. Sci. USA, vol. 89, 6457-6461, (1992).
Mottonen et al., Comparison of Combination Therapy with Single-Drug Therapy in Early Rheumatoid Arthritis: A Randomised Trial, The Lancet, vol. 353, 1568-1573, (1999).
Mummidi, et al., J. Biological Chemistry, 2000, vol. 275, pp. 18946-18961.
Nakamachi et al., Specific Increase in Enxymatic Activity of Adenosine Deaminase 1 in Rheumatoid Synovial Fibroblasts, Arthritis and Rheumatism, vol. 48., No. 3, 668-674, (2003).
Netwon-Cheh et al., Genetic Association Studies of Complex Traits: Design and Analysis Issues, Mutation Research, vol. 573, 54-69, (2005).
O'Dell et al., Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalzine and Hydroxychloroquine, or a Combination of all three Medications, New Engl. J. Med., vol. 334, No. 20, 1287-1291, (1996).
Pepe et al., Am. J. Epidemiology 159:882-890 (2004).
Pincus et al., Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis, Clinical and Experimental Rheumatology, vol. 21, Suppl. 31, S179-S185, (2003).
Pincus, Long-Term Outcomes in Rheumatoid Arthritis, British Journal of Rheumatology, vol. 34 Suppl. 2, 59-73, (1995).
Puolakka et al., Early Suppression of Disease Activity is Essential for Maintenance of Work Capacity in Patients with Recent-Onset Rheumatoid Arthritis, Arthritis & Rheumatism, vol. 52, No. 1, 36-41, (2005).
Riksen et al, Arthritis Rheum., Letters, 2006, pp. 694-695.
Rocha et al., Pharmacogenetics of outcome in children with acute lymphoblastic leukemia, Blood, vol. 105, 4752-4758, (2005).
Smolen et al., Therapeutic Strategies in early Rheumatoid Arthritis, Best Practice & Research Clinical Rheumatology, vol. 19, No. 1, 163-177, (2005).
Urano et al., Polymorphisms in the methylenetetrahdrofolate reductase, gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as e
Guchelaar Hendrik Jan
Huizinga Tom Willem Johannes
Academisch Ziekenhuis Leiden H.O.D.N. LUMC
Bausch Sarae
McDonnell Boehnen & Hulbert & Berghoff LLP
LandOfFree
Genetic markers for prognosis of antifolate treatment efficacy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetic markers for prognosis of antifolate treatment efficacy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic markers for prognosis of antifolate treatment efficacy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4287911